Conditions: Diabetes Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 413
Healthy volunteers: no

Brief summary:
This trial is conducted in Europe and North America. The aim of this trial is to compare the efficacy and safety of adding liraglutide versus addition of insulin aspart with the largest meal to insulin degludec in subjects with type 2 diabetes.

Eligible subjects with an HbA1c equal to or above 7% at end of treatment in NN1250-3643 (NCT01193309) trial will be randomised to receive treatment intensification while subjects with an HbA1c below 7% at end of treatment in NN1250-3643 (NCT01193309) may continue to receive insulin degludec treatment. Subjects are to continue their pre-trial metformin treatment.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: insulin degludec intervention 2: insulin aspart intervention 3: liraglutide
Intervention descriptions: intervention 1: Injected s.c. (under the skin) once daily. The doses will be individually adjusted intervention 2: Injected s.c. (under the skin) once daily. The doses will be individually adjusted. intervention 3: Injected s.c. (under the skin) once daily. The doses will be individually adjusted.

Protocol document: